10) Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary
myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and
Treatment. Blood. 2009;113:2895-2901.
11) Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict
survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for
Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703-1708.
12) Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic
Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype,
platelet count, and transfusion status. J Clin Oncol. 2011;29:392-397.
13) Hernandez-Boluda JC, Pereira A, Gomez M, et al. The International Prognostic Scoring System
does not accurately discriminate different risk categories in patients with post-essential
thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica. 2014;99:e55–e57.
14) Gowin K, Coakley M, Kosiorek H, et al. Discrepancies of applying primary myelofibrosis
prognostic scores for patients with post polycythemia vera/ essential thrombocytosis myelofibrosis.
Haematologica 2016;101:e405-e406.
15) Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict
survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Leukemia. 2017;31:2726–2731.
16) Passamonti F, Mora B, Giorgino T, et al. Driver mutations’ effect in secondary myelofibrosis:
an international multicenter study based on 781 patients. Leukemia. 2017;31:970-973.
17) Mora B, Giorgino T, Guglielmelli P, et al. Value of cytogenetic abnormalities in post-polycythemia
vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
Haematologica. 2018;103:e392–e394
18) Barraco D, Mora B, Guglielmelli P, et al. Gender effect on phenotype and genotype in patients
with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the
MYSEC project. Blood Cancer J. 2018 Sep 21;8(10):89
19) Mora B, Guglielmelli P, Rumi E, et al. Impact of bone marrow fibrosis grade in post-polycythemia
vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.
Am J Hematol. 2020 Jan;95:E1-E3.
20) Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. Blood
Adv. 2016;1:105-111.
21) Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary
myelofibrosis. Leukemia 2013;27:1861-1869.
22) Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular
prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014; 28:
1494-1500.
23) Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international
prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol.
2018;36:310-318.
24) Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced
international prognostic scoring system for primary myelofibrosis. J Clin Oncol.
2018;36:1769-1770.
25) Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system
for primary myelofibrosis. Leukemia. 2018;32:1631-1642.
26) Rotunno G, Pacilli A, Artusi V, et al. Epidemiology and clinical relevance of mutations in post-polycythemia
vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the
AGIMM group. Am J Hematol. 2016;91:681-668.
27) Courtier F, Garnier S, Carbuccia N, et al. Targeted molecular characterization shows differences
between primary and secondary myelofibrosis. Genes Chromosomes Cancer. 2019;
doi:10.1002/gcc.22789 Epub ahead of print
28) Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical-molecular transplant
scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133:2233-2242.
29) Passamonti F. Stem cell transplant in MF: it’s time to personalize. Blood 2019;133:2118-2120.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES